Elevar Therapeutics Announces Three Abstracts Accepted for Presentation at ESMO Congress 2026

ConferencePositive

AI Analysis

Summary

Elevar Therapeutics announced acceptance of three abstracts for presentation at the 2026 ESMO Congress in Madrid, scheduled for October 23-27. The company is a majority-owned subsidiary of HLB Co., Ltd. focused on cancer therapeutics.

Outcome Details

Three abstracts accepted for presentation at ESMO Congress 2026

Importance:3/10

Sentiment:

0.30

conference presentationoncologyESMOabstract acceptance

Related Companies

$INBP $DFPH $MDCE

Read the original article

Published by GlobeNewswire Pharma on July 27, 2026 6:14 PM

Read Original